StreetInsider.com News Articles

Form 8-K Esperion Therapeutics, For: Jun 02

Tue, 09 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260609/26623520.html

Form 8-K Esperion Therapeutics, For: Jun 02

Tue, 09 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260609/26623520.html

Form SCHEDULE 13G Esperion Therapeutics, Filed by: GLAZER CAPITAL, LLC

Mon, 08 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260608/26618319.html

Form SCHEDULE 13G Esperion Therapeutics, Filed by: GLAZER CAPITAL, LLC

Mon, 08 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260608/26618319.html

Form DEFM14A Esperion Therapeutics,

Mon, 08 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260608/26613798.html

Form DEFM14A Esperion Therapeutics,

Mon, 08 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260608/26613798.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: Shepard Jay

Mon, 01 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260601/26584057.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: Shepard Jay

Mon, 01 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260601/26584057.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: THOMPSON JOHN CRAIG

Mon, 01 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260601/26584059.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: THOMPSON JOHN CRAIG

Mon, 01 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260601/26584059.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: Fischer Seth H. Z.

Mon, 01 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260601/26584038.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: Fischer Seth H. Z.

Mon, 01 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260601/26584038.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: Hoffman Robert E.

Mon, 01 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260601/26584044.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: Hoffman Robert E.

Mon, 01 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260601/26584044.html

Form 8-K Esperion Therapeutics, For: May 28

Mon, 01 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260601/26584016.html

Form 8-K Esperion Therapeutics, For: May 28

Mon, 01 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260601/26584016.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: CARROLL J MARTIN

Mon, 01 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260601/26584024.html

Form 4 Esperion Therapeutics, For: May 28 Filed by: CARROLL J MARTIN

Mon, 01 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260601/26584024.html

Form PREM14A Esperion Therapeutics, For: May 29

Fri, 29 May 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260529/26576567.html

Form PREM14A Esperion Therapeutics, For: May 29

Fri, 29 May 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260529/26576567.html

Esperion presents pediatric bempedoic acid data at European congress

Tue, 26 May 2026 08:00:16 -0400

Esperion Therapeutics (NASDAQ: ESPR) presented data from a Phase 2 study of bempedoic acid in children and a secondary analysis from its CLEAR Outcomes trial at the European Atherosclerosis Society Congress 2026 in Athens, Greece.

The pediatric study examined bempedoic acid in children aged 6-17 years with heterozygous familial hypercholesterolemia. The variable dosing based on patient weight resulted in similar drug exposure levels to adults and reduced LDL cholesterol by 6-25% when added to existing lipid-lowering treatments. The company stated the drug was well tolerated and did not raise new safety concerns.

A secondary analysis of the CLEAR Outcomes trial found that

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

Tue, 26 May 2026 08:00:00 -0400

– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years –

– A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin Intolerant Adults –

ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an additional post hoc analysis from CLEAR Outcomes describing patient traits associated an enhanced LDL-C lowering with bempedoic acid. These data were presented as moderated

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

Tue, 26 May 2026 08:00:00 -0400

– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years –

– A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin Intolerant Adults –

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 14 May 2026 16:30:00 -0400

ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.

The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Each RSU

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 14 May 2026 16:30:00 -0400

Each RSU